| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db0f30833dc7c6315406bf7bc2bad6ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ccd56851114d89a9a5ca18141ce4b6b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcf9398876a12531cbe3cb02cea2b66d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f112e3f4a3d7c6f37a3b5754cf05796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc45aea99aa62fd2449b744d33156f7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9ef6eb38329d616c4f546098308e047 |
| publicationDate |
2012-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2010329925-A1 |
| titleOfInvention |
Trispecific therapeutics against acute myeloid leukaemia |
| abstract |
The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a V domain linked to a V domain, wherein the immunoglobulin domain specifically binds to CD123; a second immunoglobulin domain comprising a V domain linked to a V domain, wherein the immunoglobulin domain specifically binds to CD16; and a third immunoglobulin domain comprising a V domain linked to a V domain, wherein the immunoglobulin domain specifically binds to CD33. The present invention furthermore relates to a nucleic acid molecule encoding the molecule of the invention. In addition, the present invention relates to diagnostic and pharmaceutical compositions and the use of the molecule or the nucleic acid molecule of the invention in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome. |
| priorityDate |
2009-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |